133 related articles for article (PubMed ID: 31423335)
21. Post-marketing surveillance of the safety and effectiveness of naldemedine in the management of opioid-induced constipation in patients with cancer pain in Japan.
Takata K; Nakazawa M; Honda K; Hashimoto S
Support Care Cancer; 2022 May; 30(5):3943-3954. PubMed ID: 35044484
[TBL] [Abstract][Full Text] [Related]
22. Efficacy of Treatments for Opioid-Induced Constipation: Systematic Review and Meta-analysis.
Nee J; Zakari M; Sugarman MA; Whelan J; Hirsch W; Sultan S; Ballou S; Iturrino J; Lembo A
Clin Gastroenterol Hepatol; 2018 Oct; 16(10):1569-1584.e2. PubMed ID: 29374616
[TBL] [Abstract][Full Text] [Related]
23. Spotlight on naldemedine in the treatment of opioid-induced constipation in adult patients with chronic noncancer pain: design, development, and place in therapy.
Stern EK; Brenner DM
J Pain Res; 2018; 11():195-199. PubMed ID: 29391826
[TBL] [Abstract][Full Text] [Related]
24. A randomized, placebo-controlled phase 3 trial (Study SB-767905/013) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
Irving G; Pénzes J; Ramjattan B; Cousins M; Rauck R; Spierings EL; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
J Pain; 2011 Feb; 12(2):175-84. PubMed ID: 21292168
[TBL] [Abstract][Full Text] [Related]
25. Efficacy and Safety of Naldemedine for Patients with Cancer with Opioid-Induced Constipation in Clinical Practice: A Real-World Retrospective Study.
Nishiba H; Imai H; Fujita Y; Hiruta E; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Mogi J; Minato K; Obayashi K
J Clin Med; 2022 May; 11(9):. PubMed ID: 35566798
[TBL] [Abstract][Full Text] [Related]
26. Efficacy and Safety of Lubiprostone in Patients with Opioid-Induced Constipation: Phase 3 Study Results and Pooled Analysis of the Effect of Concomitant Methadone Use on Clinical Outcomes.
Spierings ELH; Drossman DA; Cryer B; Mazen Jamal M; Losch-Beridon T; Mareya SM; Wang M
Pain Med; 2018 Jun; 19(6):1184-1194. PubMed ID: 29016868
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and safety of naloxegol in patients with opioid-induced constipation and laxative-inadequate response.
Tack J; Lappalainen J; Diva U; Tummala R; Sostek M
United European Gastroenterol J; 2015 Oct; 3(5):471-80. PubMed ID: 26535126
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Lubiprostone for the Treatment of Opioid-Induced Constipation, Analyzed by Opioid Class.
Webster LR; Brewer RP; Lichtlen P; Losch-Beridon T; Mareya S; Wang M
Pain Med; 2018 Jun; 19(6):1195-1205. PubMed ID: 29897589
[TBL] [Abstract][Full Text] [Related]
29. Real-World Patient Characteristics and Treatment Patterns of Naldemedine for the Treatment of Opioid-Induced Constipation in Patients with Cancer: A Multicenter Retrospective Chart Review Study.
Hiruta E; Fujita Y; Imai H; Masuno T; Yamazaki S; Tanaka H; Kamiya T; Ito M; Takei S; Matsuura M; Nishiba H; Mogi J; Kotake M; Koizuka S; Minato K
Medicina (Kaunas); 2021 Nov; 57(11):. PubMed ID: 34833451
[No Abstract] [Full Text] [Related]
30. Naldemedine-induced opioid withdrawal syndrome with severe psychiatric symptoms in an advanced cervical cancer patient without brain metastasis.
Ishida M; Hiraoka M; Yaguchi A; Sugano K; Adachi N; Itoga T; Ishiguro T; Onishi H
Palliat Support Care; 2022 Jun; 20(3):445-447. PubMed ID: 34955117
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and safety of naloxegol for opioid-induced constipation assessed by specific opioid medication, opioid dose, and duration of opioid use.
Nalamachu S; Gudin J; Datto C; Coyne K; Poon JL; Hu Y
J Opioid Manag; 2018; 14(3):211-221. PubMed ID: 30044486
[TBL] [Abstract][Full Text] [Related]
32. Influence of Brain Metastasis on Analgesia-Related Outcomes in Patients with Lung and Breast Cancers Treated with Naldemedine: A Propensity Score-Matched Analysis.
Hanamoto A; Koseki T; Utsunomiya A; Ishihara T; Tobe T; Kondo M; Kijima Y; Matsuoka H; Mizuno T; Hayashi T; Yamada S
J Clin Med; 2023 Nov; 12(22):. PubMed ID: 38002612
[TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of elobixibat for chronic constipation: results from a randomised, double-blind, placebo-controlled, phase 3 trial and an open-label, single-arm, phase 3 trial.
Nakajima A; Seki M; Taniguchi S; Ohta A; Gillberg PG; Mattsson JP; Camilleri M
Lancet Gastroenterol Hepatol; 2018 Aug; 3(8):537-547. PubMed ID: 29805116
[TBL] [Abstract][Full Text] [Related]
34. A randomized, placebo-controlled phase 3 trial (Study SB-767905/012) of alvimopan for opioid-induced bowel dysfunction in patients with non-cancer pain.
Jansen JP; Lorch D; Langan J; Lasko B; Hermanns K; Kleoudis CS; Snidow JW; Pierce A; Wurzelmann J; Mortensen ER
J Pain; 2011 Feb; 12(2):185-93. PubMed ID: 21292169
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and Safety of Peripherally Acting Mu-Opioid Receptor Antagonists for the Treatment of Opioid-Induced Constipation: A Bayesian Network Meta-analysis.
Ouyang R; Li Z; Huang S; Liu J; Huang J
Pain Med; 2020 Nov; 21(11):3224-3232. PubMed ID: 32488259
[TBL] [Abstract][Full Text] [Related]
36. Effectiveness of Naldemedine Compared with Magnesium Oxide in Preventing Opioid-Induced Constipation: A Randomized Controlled Trial.
Ozaki A; Kessoku T; Tanaka K; Yamamoto A; Takahashi K; Takeda Y; Kasai Y; Iwaki M; Kobayashi T; Yoshihara T; Kato T; Suzuki A; Honda Y; Ogawa Y; Fuyuki A; Imajo K; Higurashi T; Yoneda M; Taguri M; Ishiki H; Kobayashi N; Saito S; Ichikawa Y; Nakajima A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565243
[TBL] [Abstract][Full Text] [Related]
37. Naldemedine and Magnesium Oxide as First-Line Medications for Opioid-Induced Constipation: A Comparative Database Study in Japanese Patients With Cancer Pain.
Kessoku T; Higashibata T; Morioka Y; Naya N; Koretaka Y; Ichikawa Y; Hisanaga T; Nakajima A
Cureus; 2024 Mar; 16(3):e55925. PubMed ID: 38601408
[TBL] [Abstract][Full Text] [Related]
38. Efficacy and Tolerability of Subcutaneous Methylnaltrexone in Patients with Advanced Illness and Opioid-Induced Constipation: A Responder Analysis of 2 Randomized, Placebo-Controlled Trials.
Nalamachu SR; Pergolizzi J; Taylor R; Slatkin NE; Barrett AC; Yu J; Bortey E; Paterson C; Forbes WP
Pain Pract; 2015 Jul; 15(6):564-71. PubMed ID: 24815199
[TBL] [Abstract][Full Text] [Related]
39. A randomized, placebo-controlled trial of lubiprostone for opioid-induced constipation in chronic noncancer pain.
Jamal MM; Adams AB; Jansen JP; Webster LR
Am J Gastroenterol; 2015 May; 110(5):725-32. PubMed ID: 25916220
[TBL] [Abstract][Full Text] [Related]
40. Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials.
Kahaly GJ; Douglas RS; Holt RJ; Sile S; Smith TJ
Lancet Diabetes Endocrinol; 2021 Jun; 9(6):360-372. PubMed ID: 33865501
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
